Levels of mRNA for dopaminergic receptor D5 in circulating lymphocytes may be associated with subsequent response to interferon-β in patients with multiple sclerosis

Journal of Neuroimmunology

Volumn 277, Issue 1-2, 2014, Pages 193-196

  Cosentino, Marco ^a   Zaffaroni, Mauro ^b   Marino, Franca ^a  

^a UNIVERSITY OF INSUBRIA   (Italy)

^b Azienda Ospedaliera S Antonio Abate di Gallarate   (Italy)

Author keywords

Dopaminergic receptors; Interferon beta; Lymphocytes; Multiple sclerosis; Tyrosine hydroxylase; 2 Adrenoceptors

Indexed keywords

BETA 2 ADRENERGIC RECEPTOR; BETA INTERFERON; BETA1A INTERFERON; BIOLOGICAL MARKER; DOPAMINE 1 RECEPTOR; DOPAMINE 3 RECEPTOR; DOPAMINE 5 RECEPTOR; FINGOLIMOD; GLATIRAMER; INTERFERON BETA SERINE; MESSENGER RNA; NATALIZUMAB; TYROSINE 3 MONOOXYGENASE; ANTIBODY; DOPAMINE 2 RECEPTOR; IMMUNOLOGIC FACTOR;

ADULT; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; EXPANDED DISABILITY STATUS SCALE; FEMALE; HUMAN; HUMAN CELL; LYMPHOCYTE; LYMPHOCYTE FUNCTION; MALE; MIDDLE AGED; MULTIPLE SCLEROSIS; PERIPHERAL BLOOD MONONUCLEAR CELL; PROTEIN ANALYSIS; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; TREATMENT DURATION; TREATMENT RESPONSE; DRUG EFFECTS; GENETICS; IMMUNOLOGY; METABOLISM; PATHOLOGY; RECEIVER OPERATING CHARACTERISTIC; YOUNG ADULT;

ADULT; ANTIBODIES; FEMALE; HUMANS; IMMUNOLOGIC FACTORS; INTERFERON-BETA; LYMPHOCYTES; MALE; MIDDLE AGED; MULTIPLE SCLEROSIS; RECEPTORS, ADRENERGIC, BETA-2; RECEPTORS, DOPAMINE D2; RECEPTORS, DOPAMINE D5; RNA, MESSENGER; ROC CURVE; TYROSINE 3-MONOOXYGENASE; YOUNG ADULT;

EID: 84919337664     PISSN: 01655728     EISSN: 18728421     Source Type: Journal    
DOI: 10.1016/j.jneuroim.2014.10.009     Document Type: Article

References (26)

1. Arnason B.G. Interferon beta in multiple sclerosis. Neurology 1993, 43:641-643.
2. Beaulieu J.-M., Gainetdinov R.R. The physiology, signaling, and pharmacology of dopamine receptors. Pharmacol. Rev. 2011, 63:182-217.
3. Cosentino M., Marino F. Adrenergic and dopaminergic modulation of immunity in multiple sclerosis: teaching old drugs new tricks?. J. Neuroimmune Pharm. 2013, 8:163-179.
4. Cosentino M., Zaffaroni M., Marino F., Bombelli R., Ferrari M., Rasini E., Lecchini S., Ghezzi A., Frigo G. Catecholamine production and tyrosine hydroxylase expression in peripheral blood mononuclear cells from multiple sclerosis patients: effect of cell stimulation and possible relevance for activation-induced apoptosis. J. Neuroimmunol. 2002, 133:233-240.
5. Cosentino M., Zaffaroni M., Ferrari M., Marino F., Bombelli R., Rasini E., Frigo G., Ghezzi A., Comi G., Lecchini S. Interferon-γ and interferon-β affect endogenous catecholamines in human peripheral blood mononuclear cells: implications for multiple 1sclerosis. J. Neuroimmunol. 2005, 162:112-121.
6. Frohman E.M., Racke M.K., Raine C.S. Multiple sclerosis-the plaque and its pathogenesis. N. Engl. J. Med. 2006, 354:942-955.
7. Giorelli M., Livrea P., Trojano M. Post-receptorial mechanisms underlie functional disregulation of beta2-adrenergic receptors in lymphocytes from Multiple Sclerosis patients. J. Neuroimmunol. 2004, 155:143-149.
8. Giorelli M., Livrea P., Trojano M. Dopamine fails to regulate activation of peripheral blood lymphocytes from multiple sclerosis patients: effects of IFN-beta. J. Interferon Cytokine Res. 2005, 25:395-406.
9. Harrell F.E., Califf R.M., Pryor D.B., Lee K.L., Rosati R.A. Evaluating the yield of medical tests. JAMA 1982, 247:2543-2546.
10. Harrison D.M. Multiple sclerosis. Ann. Intern. Med. 2014, 160. (ITC4-2-ITC4-18).
11. Hemmer B., Nessler S., Zhou D., Kieseier B., Hartung H.P. Immunopathogenesis and immunotherapy of multiple sclerosis. Nat. Clin. Pract. Neurol. 2006, 2:201-211.
12. Jacobs L.D., Cookfair D.L., Rudick R.A., Herndon R.M., Richert J.R., Salazar A.M., Fischer J.S., Goodkin D.E., Granger C.V., Simon J.H., Emrich L.J., Bartoszak D.M., Bourdette D.N., Braiman J., Brownscheidle C.M., Coats M.E., Cohan S.L., Dougherty D.S., Kinkel R.P., Mass M.K., Munschauer F.E., Priore R.L., Pullicino P.M., Scherokman B.J., Weinstock-Guttman B., Whitham R.H. A phase III trial of intramuscular recombinant interferon beta as treatment for exacerbating-remitting multiple sclerosis: design and conduct of study and baseline characteristics of patients. Multiple Sclerosis Collaborative Research Group (MSCRG). Mult. Scler. 1995, 1:118-135.
13. Kantarci O.H., Pirko I., Rodriguez M. Novel immunomodulatory approaches for the management of multiple sclerosis. Clin. Pharmacol. Ther. 2014, 95:32-44.
14. Kebir H., Kreymborg K., Ifergan I., Dodelet-Devillers A., Cayrol R., Bernard M., Giuliani F., Arbour N., Becher B., Prat A. Human TH17 lymphocytes promote blood-brain barrier disruption and central nervous system inflammation. Nat. Med. 2007, 13:1173-1175.
15. Kurtzke J.F. Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology 1983, 33:1444-1452.
16. Lassmann H., Ransohoff R.M. The CD4-Th1 model for multiple sclerosis: a critical re-appraisal. Trends Immunol. 2004, 25:132-137.
17. Levite M., Chowers Y., Ganor Y., Besser M., Hershkovits R., Cahalon L. Dopamine interacts directly with its D3 and D2 receptors on normal human T cells, and activates β-integrin function. Eur. J. Immunol. 2001, 31:3504-3512.
18. Naismith R.T. Multiple sclerosis therapeutic strategies: start safe and effective, reassess early, and escalate if necessary. Neurol. Clin. Pract. 2011, 1:69-71.
19. Noseworthy J.H., Lucchinetti C., Rodriguez M., Weinshenker B.G. Multiple sclerosis. N. Engl. J. Med. 2000, 343:938-952.
20. Nylander A., Hafler D.A. Multiple sclerosis. J. Clin. Invest. 2012, 122:1180-1188.
21. Prosperini L., Capobianco M., Gianni C. Identifying responders and nonresponders to interferon therapy in multiple sclerosis. Deg. Neurol. Neuromusc. Dis. 2014, 2014(4):75-84.
22. Río J., Nos C., Tintoré M., Borrás C., Galán I., Comabella M., Montalban X. Assessment of different treatment failure criteria in a cohort of relapsing-remitting multiple sclerosis patients treated with interferon beta: implications for clinical trials. Ann. Neurol. 2002, 52:400-406.
23. Rudick R.A., Polman C.H. Current approaches to the identification and management of breakthrough disease in patients with multiple sclerosis. Lancet Neurol. 2009, 8:545-559.
24. Saha B., Mondal A.C., Basu S., Dasgupta P.S. Circulating dopamine level, in lung carcinoma patients, inhibits proliferation and cytotoxicity of CD4+ and CD8+ T cells by D1 dopamine receptors: an in vitro analysis. Int. Immunopharmacol. 2001, 1:1363-1374.
25. Tzartos J.S., Friese M.A., Craner M.J., Palace J., Newcombe J., Esiri M.M., Fugger L. Interleukin-17 production in central nervous system-infiltrating T cells and glial cells is associated with active disease in multiple sclerosis. Am. J. Pathol. 2008, 172:146-155.
26. Zaffaroni M., Marino F., Bombelli R., Rasini E., Monti M., Ferrari M., Ghezzi A., Comi G., Lecchini S., Cosentino M. Therapy with interferon-beta modulates endogenous catecholamines in lymphocytes of patients with multiple sclerosis. Exp. Neurol. 2008, 214:315-321.